FcRn

Immunotherapy strategies for autoimmune disorders of the nervous system 1:43
Immunotherapy strategies for autoimmune disorders of the nervous system
Divyanshu Dubey • 12 Apr 2022
cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD 1:32
cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD
Michael Levy • 25 Feb 2022
The expanding treatment landscape for myasthenia gravis 2:11
The expanding treatment landscape for myasthenia gravis
James F. Howard Jr. • 7 Apr 2021
Impact of fcRn inhibitors on IgG-mediated autoimmune disorders 0:45
Impact of fcRn inhibitors on IgG-mediated autoimmune disorders
James F. Howard Jr. • 7 Apr 2021
ADAPT analysis: efgartigimod for generalized myasthenia gravis 4:59
ADAPT analysis: efgartigimod for generalized myasthenia gravis
James F. Howard Jr. • 7 Apr 2021
The content of VJNeurology is intended for healthcare professionals